Hiroe Amou

918 total citations
16 papers, 633 citations indexed

About

Hiroe Amou is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Hiroe Amou has authored 16 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Hematology and 7 papers in Oncology. Recurrent topics in Hiroe Amou's work include Multiple Myeloma Research and Treatments (9 papers), Bone health and treatments (3 papers) and Bone Metabolism and Diseases (3 papers). Hiroe Amou is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Bone health and treatments (3 papers) and Bone Metabolism and Diseases (3 papers). Hiroe Amou collaborates with scholars based in Japan. Hiroe Amou's co-authors include Toshio Matsumoto, Kyoko Takeuchi, Masahiro Abe, Shuji Ozaki, Ayako Nakano, Asuka Oda, Masahiro Hiasa, Kumiko Kagawa, Takeshi Harada and Hirokazu Miki and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Hiroe Amou

16 papers receiving 618 citations

Peers

Hiroe Amou

ONCOL

HEMAT

IMMUN

Asuka Oda Japan

Yoko Okitsu Japan

Jumpei Teramachi Japan

Yusuke Kamihara Japan

Masaharu Nobuyoshi Japan

Katharina M. Brauer Germany

Ramapriya Ganti United States

Shidai Mu China

Fiorella D’Auria Italy

Weihong Zhang China

Asuka Oda Japan

Hiroe Amou

353 ×1.1

310 ×1.0

ONCOL

281 ×1.1

HEMAT

142 ×1.1

120 ×1.3

IMMUN

Citations per year, relative to Hiroe Amou Hiroe Amou (= 1×) peers Asuka Oda

Countries citing papers authored by Hiroe Amou

Since Specialization

Citations

This map shows the geographic impact of Hiroe Amou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroe Amou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroe Amou more than expected).

Fields of papers citing papers by Hiroe Amou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroe Amou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroe Amou. The network helps show where Hiroe Amou may publish in the future.

Co-authorship network of co-authors of Hiroe Amou

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroe Amou. A scholar is included among the top collaborators of Hiroe Amou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroe Amou. Hiroe Amou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Hattori, Takefumi, et al.. (2016). A biosynthetic pathway for (E)-methyl cinnamate formation in the ectomycorrhizal fungus Tricholoma matsutake. Mycoscience. 57(3). 181–186. 3 indexed citations

Nakamura, Shingen, Hirokazu Miki, Shinsuke Kido, et al.. (2013). Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. International Journal of Hematology. 98(1). 66–73. 13 indexed citations

Nakano, Ayako, Hirokazu Miki, Shingen Nakamura, et al.. (2012). Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. Journal of Bioenergetics and Biomembranes. 44(1). 31–38. 36 indexed citations

Kagawa, Kumiko, Ayako Nakano, Hirokazu Miki, et al.. (2012). Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL. PLoS ONE. 7(2). e31594–e31594. 10 indexed citations

Miki, Hirokazu, Shuji Ozaki, Shingen Nakamura, et al.. (2011). KRN5500, a spicamycin derivative, exerts anti‐myeloma effects through impairing both myeloma cells and osteoclasts. British Journal of Haematology. 155(3). 328–339. 4 indexed citations

Nakano, Ayako, Masahiro Abe, Asuka Oda, et al.. (2011). Delayed treatment with vitamin C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. International Journal of Hematology. 93(6). 727–735. 22 indexed citations

Nakano, Akitoshi, Hiroe Amou, Masahiro Hiasa, et al.. (2011). The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 25(7). 1182–1188. 82 indexed citations

Cui, Qu, Hironobu Shibata, Asuka Oda, et al.. (2011). Targeting myeloma–osteoclast interaction with Vγ9Vδ2 T cells. International Journal of Hematology. 94(1). 63–70. 12 indexed citations

Nakano, Ayako, Daisuke Tsuji, Hirokazu Miki, et al.. (2011). Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells. PLoS ONE. 6(11). e27222–e27222. 90 indexed citations

10.

Harada, Takeshi, Shuji Ozaki, Asuka Oda, et al.. (2011). Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity. Blood. 118(21). 1833–1833. 1 indexed citations

11.

Takeuchi, Kyoko, Masahiro Abe, Masahiro Hiasa, et al.. (2010). TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth. PLoS ONE. 5(3). e9870–e9870. 108 indexed citations

12.

Hiasa, Masahiro, Masahiro Abe, Ayako Nakano, et al.. (2009). GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE). Blood. 114(20). 4517–4526. 95 indexed citations

13.

Kitazoe, Ken-ichi, Masahiro Abe, Masahiro Hiasa, et al.. (2008). Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. International Journal of Hematology. 89(1). 45–57. 25 indexed citations

14.

Tanaka, Yoïchi, Masahiro Abe, Masahiro Hiasa, et al.. (2007). Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin. Clinical Cancer Research. 13(3). 816–823. 129 indexed citations

15.

Takeuchi, Kyoko, Masahiro Abe, Asuka Oda, et al.. (2006). SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.. Blood. 108(11). 3479–3479. 2 indexed citations

16.

Kitazoe, Ken-ichi, Masahiro Abe, Kumiko Kagawa, et al.. (2006). Emerging of Valproic Acid as an Anti-Myeloma Agent.. Blood. 108(11). 3482–3482. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact